Galapagos NV ADR

Price Chart

Risk-Adjusted Performance

Also Listed On

Galapagos NV ADR (GLPG) Price Performance

Galapagos NV ADR (GLPG) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $29.80, down 6.90% from the previous close.

Over the past year, GLPG has traded between a low of $23.04 and a high of $37.62. The stock has gained 18.6% over this period. It is currently 20.8% below its 52-week high.

Galapagos NV ADR has a market capitalization of $2.11B.

About Galapagos NV ADR

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.